Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models

BACKGROUND: Signaling through mTOR and somatostatin pathway is implicated in thyroid cancer development. METHOD: We evaluated everolimus, an mTOR inhibitor and pasireotide, a multi receptor somatostatin analogue as potential therapy of thyroid cancer focusing on the in vitro and in vivo efficacy, as...

Descripción completa

Detalles Bibliográficos
Autores principales: Owonikoko, Taofeek K., Zhang, Guojing, Lallani, Shenila B., Chen, Zhengjia, Martinson, Deborah E., Khuri, Fadlo R., Lonial, Sagar, Marcus, Adam, Sun, Shi-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390992/
https://www.ncbi.nlm.nih.gov/pubmed/30807575
http://dx.doi.org/10.1371/journal.pone.0206309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390992/
https://www.ncbi.nlm.nih.gov/pubmed/30807575
http://dx.doi.org/10.1371/journal.pone.0206309

Ejemplares similares